SEC Comment Letter for Vaxart, (VXRT) — Jan 29, 2021

Vaxart, Inc.
Date: Jan. 29, 2021 · CIK: 0000072444 · Accession: 0000000000-21-001113

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-35285

Date

January 29, 2021

Author

Andrei Floroiu

Form

UPLOAD

Company

Vaxart, Inc.

Letter

United States securities and exchange commission logo January 29, 2021 Andrei Floroiu Chief of Executive Officer Vaxart, Inc. 385 Oyster Point Boulevard Suite 9A South San Francisco, CA 94080 Re:Vaxart, Inc. Form 10-K for the fiscal year ended December 31, 2019 File No. 001-35285 Dear Mr. Floroiu: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
January 29, 2021
Andrei Floroiu
Chief of Executive Officer
Vaxart, Inc.
385 Oyster Point Boulevard
Suite 9A
South San Francisco, CA 94080
Re:Vaxart, Inc.
Form 10-K for the fiscal year ended December 31, 2019
File No. 001-35285
Dear Mr. Floroiu:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io